Quintiles joins forces with Archimedes to quantify healthcare decisions

Quintiles has formed a partnership with a San Francisco-based healthcare modeling company to offer a new range of services aimed at reducing the time and expense of bring new therapies to market.

The biopharmaceutical services company will use Archimedes's technology to capture “predictive simulations from real-world research”, said global head of integrated clinical services Rick Sax.

“Turning data into insights will allow customers to make faster, better decisions across the product lifecycle and increase their probability of success,” he added.

Quintiles will promote and provide access to Archimedes' ARCHeS Innovator technology, which enables users to run clinically realistic virtual trials.

Mika Newton, vice president, ARCHeS and consulting business leader for Archimedes, said: “Biopharma companies are under enormous pressure to maximise the efficiency and strategic positioning of products they are developing and marketing.

“This partnership between Archimedes and Quintiles makes advanced simulation modeling and premier medical evidence accessible and fully integrated into customers' clinical research and commercial activities.”

Archimedes is a spin-off of the US managed care consortium Kaiser Permanente and has worked with the FDA, Novo Nordisk and Bristol-Myers Squibb.